Filing Flows › Sutro Biopharma (STRO) › Q2 2026 › vs Q1 2026
Sutro Biopharma (STRO) Q2 2026 vs Q1 2026 (quarter over quarter)
Sutro Biopharma's revenue fell $4.7M (-32%) from $14.5M in Q1 2026 to $9.8M in Q2 2026.
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.8M | $14.5M | −$4.7M | -32% |
| Net loss | $38.5M | $38.5M | $49K | +0.1% |
| Costs & expenses | $48.4M | $53.0M | −$4.7M | -9% |
| Operating costs | $39.7M | $44.2M | −$4.5M | -10% |
| Interest & other, net | $8.6M | $8.8M | −$199K | -2% |
| Income tax | $1K | −$15K | $16K | — |
| Research & development | $31.7M | $36.6M | −$4.9M | -13% |
| General & admin | $7.8M | $7.6M | $247K | +3% |
| Operating cash sources | $41.6M | $45.1M | −$3.5M | -8% |
| Depreciation & amortization | $1.3M | $1.3M | −$16K | -1% |
| Share-based compensation | $2.0M | $1.6M | $448K | +29% |
| Cash used in operations | $38.3M | $42.3M | −$4.0M | -9% |
| Net loss absorbed | $38.5M | $38.5M | $49K | +0.1% |
| Working capital & other | $3.0M | $6.6M | −$3.6M | -54% |
Questions
How much did Sutro Biopharma's revenue grow quarter over quarter in Q2 2026?
Sutro Biopharma's revenue fell $4.7M (-32%) from $14.5M in Q1 2026 to $9.8M in Q2 2026.